Peter is a renowned drug developer and industry leader known for building world-class teams that deliver innovation and transformational medicines. Throughout his career, Peter has been at the forefront of innovative drug development reflecting a lifelong commitment to advancing science and improving the lives of patients.

Prior to Third Arc Bio, Peter served as the Global Head of Oncology R&D for Johnson & Johnson (J&J) overseeing an end-to-end research and development organization that delivered 13 new drugs to market with over 60 approvals. Over his career, Peter has delivered multiple first and best-in-class transformational medicines, including ZYTIGA®, IMBRUVICA®, DARZALEX®, DARZALEX FASPRO®, ERLEADA®, RYBREVANT®, LAZCLUZE®, CARVYKTI®, TECVAYLI®, TALVEY®, TAFINLAR®, and MEKINIST®. Peter’s innovative approach to drug development resulted in 12 FDA Breakthrough Therapy Designations and 38 New England Journal of Medicine publications for J&J medicines. These achievements underscore his ability to push the boundaries of science and deliver life changing therapies to patients.

Prior to J&J, Peter also held multiple leadership roles at GlaxoSmithKline (GSK) including Vice President, Global Head of Oncology Early Clinical Development and Vice President and Medical Development Leader in Late Development. In these roles, he successfully filed 10 Investigational New Drug applications and played a leading role in taking two medicines from early discovery through global registration trials by setting a new benchmark with a “novel-novel” drug combination approach.

Peter now also serves as a CEO partner at Omega Funds, a leading life science investment firm, and as a board director at Neomorph, a leading molecular glue company. Peter earned his MD and PhD in cell and molecular biology from the University of Pennsylvania and completed his training in internal medicine and oncology at Duke University and the National Cancer Institute.